A Two Part, Non-randomized, Open Label Study Designed to Assess the Pharmacokinetics of GSK2982772 Following Administration of Modified Release Formulations in Capsule Relative to an Immediate Release Reference Tablet Formulation (Part A) and the Pharmacokinetics of Escalating, Repeat Doses of a Selected Modified Release Prototype (Part B) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2019
At a glance
- Drugs GSK 2982772 (Primary) ; GSK 2982772 (Primary)
- Indications Inflammatory bowel diseases; Plaque psoriasis; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 08 Jan 2019 Status changed from recruiting to completed.
- 11 Oct 2018 Planned End Date changed from 31 Oct 2018 to 13 Nov 2018.
- 11 Oct 2018 Planned primary completion date changed from 31 Oct 2018 to 13 Nov 2018.